– USA, ME – Covetrus (NASDAQ: CVET), a global leader in animal health technology and services, today announced the appointment of Benjamin Wolin as chair of its board of directors effective September 4, 2019. Wolin succeeds David Evans Shaw, who will continue to serve as a director on the Covetrus board. Wolin is expected to serve in this role through the company’s 2020 annual stockholders meeting, in accordance with the company’s bylaws.
“I want to thank my father for his incredible support and guidance as we successfully brought our vision to life with the formation of Covetrus,” said Benjamin Shaw, Covetrus president and CEO. “I am also excited to further partner with Ben Wolin and other board members as our team executes our transformation plans. We are enthusiastic about the long-term value that we are creating.”
Additionally, Covetrus announced that Betsy Atkins is stepping down as a member of the company’s board of directors. Ms. Atkins’ resignation became effective as of September 4, 2019.
“On behalf of the board I extend appreciation to Betsy for her years of support and service to both Covetrus and Vets First Choice,” said David Shaw.
“As a founder and board chair of Vets First Choice, it has been a privilege to play a leadership role in the creation of Covetrus and to serve as chair of the board since inception. I look forward to remaining active as a director,” said outgoing board chair, David Shaw. “Covetrus offers a compelling and transformative value proposition in the global animal health market, and I commend management for the company’s significant pace of accomplishments since closing earlier this year. Our decision to appoint an independent chair reflects the board’s commitment to progressive corporate governance principles and a high level of board engagement to support the company’s success. Ben Wolin has deep expertise in digital healthcare, pharmacy, and technology which will benefit Covetrus as the board works actively with management to drive operational performance.”
About Ben Wolin
Wolin has extensive experience with public company board governance, as well as financial and operating expertise. Previously, Wolin was the CEO and co-founder of Everyday Health, Inc., a communications and marketing platform for consumers, doctors and healthcare companies, and a member of its board of directors for 14 years. Today, he serves on the board of directors of Diplomat Pharmacy, Inc. as lead independent director of the board, member of the audit committee, and chair of the nominating and corporate governance committee. Wolin is also chairman of the board of Rockwell Medical, Inc. and member of the board of directors of AdhereTech and SourceMedia, LLC.
“It is an exciting time at Covetrus, and I believe the company has a significant global opportunity to accelerate growth through the adoption of its unique technology and integrated supply chain platform,” said Wolin. “I am energized to lead this team of deeply-experienced board directors and more actively engage Covetrus leadership as we journey through the next phase of its transformation and continue to build long-term value for our shareholders.”
About Covetrus
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We’re bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe.
For more information: https://covetrus.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
